Voyager Therapeutics Inc. (VYGR)
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for the long haul.
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.53 per share a year ago.
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations.
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.18 per share a year ago.
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.20 per share a year ago.
Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conference Call Participants Jack Allen - Robert W. Baird Phil Nadeau - TD Cowen Pete Stavropoulos - Cantor Fitzgerald Lili Nsongo - Leerink Partners Samantha Semenkow - Citi Mehdi Goudarzi - Truist Securities Ry Forseth - Guggenheim Securities Jay Olson - Oppenheimer & Co. Patrick Trucchio - HC Wainwright & Co. Yun Zhong - Wedbush Sciences Yanan Zhu - Wells Fargo Securities Sumant Kulkarni - Canaccord Genuity Operator Good afternoon, and welcome to Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call.
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago.
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Voyager Therapeutics, Inc.'s TRACER platform shows strong preclinical results for BBB-crossing gene therapies, securing multi-billion dollar deals with Novartis and Neurocrine, but lacks clinical trial data. VY7523, a monoclonal antibody for early Alzheimer's treatment, is expected to yield Phase I results by mid-2025, with potential undervaluation of VYGR shares. The competitive landscape includes Denali, Roche, and AbbVie, with varying BBB-crossing strategies, highlighting the speculative nature of investing in early-stage neurological therapies.
